[Chronic experimentation with TRH administered intramuscularly in spinocerebellar degeneration. Double-blind cross-over study in 30 subjects].

Abstract

Thyrotropin-releasing hormone (TRH) has been reported to improve the clinical picture of patients with the predominantly cerebellar form of spinocerebellar degeneration. The authors performed a double-blind, double cross-over, four-month trial, where TRH, at the daily dose of 2 and 4 mg, and placebo were given intramuscularly over a period of one month each. Sixteen patients with Friedreich's disease and 14 patients with different forms of spinocerebellar degeneration completed the trial. Features of cerebellar involvement, such as dysarthria, dysmetria and stance ataxia, showed a slight but significant improvement during TRH treatment. TRH was well tolerated. Transient nausea was the most frequent side-effect.

• Authors: A Filla, G De Michele, L Di Martino, A Mengano, L Iorio, M A Maggio, G Campanella
• Journal: Rivista di neurologia (Riv Neurol) 1989 Mar-Apr Vol. 59 Issue 2 Pg. 83-8 ISSN: 0035-6344 [Print] Italy
• Vernacular Title: Sperimentazione cronica del TRH per via intramuscolare nelle degenerazioni spino-cerebellari. Studio in doppio cieco cross-over su 30 soggetti.
• PMID: 2505370 (Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article)

Chemical References

• Thyrotropin-Releasing Hormone

Topics

• Adolescent
• Adult
• Aged
• Double-Blind Method
• Female
• Friedreich Ataxia (drug therapy)
• Humans
• Injections, Intramuscular
• Male
• Middle Aged
• Spinocerebellar Degenerations (drug therapy)
• Thyrotropin-Releasing Hormone (administration & dosage, adverse effects, therapeutic use)